Poxel Announces Results from June 24, 2020 Ordinary Annual and Extraordinary General Meeting Jun 25, 2020
Poxel Announces Positive Pharmacokinetic (PK) / Pharmacodynamic (PD) Study Results for PXL770, a Direct AMPK Activator for the Treatment of NASH Jun 24, 2020
Poxel Announces Program Update and Preclinical Results on PXL770 for NASH Combinations and Other Metabolic Diseases May 25, 2020
Poxel Announces Publication of Imeglimin Clinical Study Results in Clinical Pharmacokinetics Apr 20, 2020
Poxel Announces Availability of 2019 Universal Registration Document and Provides Business Update Apr 20, 2020
